COMMUNIQUÉS West-GlobeNewswire

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

21/04/2025 - 14:00

GenesisX pairs clinical capability with broad accessibility in surgical robotics ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally [...]

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

21/04/2025 - 14:00

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first [...]

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat

21/04/2025 - 14:00

New “Decision to grant” communications in Europe and Japan MADRID and CAMBRIDGE, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company [...]

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

21/04/2025 - 14:00

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class 1 targeted and immune-mediated therapeutics to fight [...]

Reflect Scientific Inc. Announces Strategic Market Transition and Substantial Cost Savings

21/04/2025 - 14:00

OREM, Utah, April 21, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific Inc. (symbol: RSCF), a leading innovator in advanced refrigeration and cooling technologies, today announced significant financial improvements resulting [...]

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

21/04/2025 - 14:05

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 following alignment on [...]

Sofwave’s SUPERB™ Non-Invasive Skin Treatment Technology Receives Regulatory Clearance in Japan Significantly Expanding its Coverage of the APAC Region

21/04/2025 - 14:30

Japan represents third largest non-surgical medical aesthetic market in the world SAN CLEMENTE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy- [...]

AP Bioscience to Present New Preclinical Data at American Association of Cancer Research Annual Meeting

21/04/2025 - 14:30

TAIPEI, Taiwan, April 21, 2025 (GLOBE NEWSWIRE) -- AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative bispecific antibodies, today announced that it [...]

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

21/04/2025 - 14:30

Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed [...]

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

21/04/2025 - 14:45

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D [...]

Eascra Biotech Receives U.S. National Science Foundation Grant

21/04/2025 - 15:00

R&D funding accelerates the transition from research to impact BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Eascra Biotech announced today that they have been awarded a U.S. National Science Foundation (NSF) Small [...]

PathAI Announces Poster Presentations at the 2025 American Association of Cancer Research Annual Meeting

21/04/2025 - 15:00

BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology solutions, today announced it will present research from the outputs of PathAI's pathology universal transformer (PLUTO) [...]

Senti Bio Participates in a Virtual Investor KOL Connect Segment

21/04/2025 - 15:05

Moderated discussion with Stephen Strickland, MD, MSCI, internationally respected leukemia researcher, Director of Leukemia Research for Sarah Cannon Research Institute and Kanya Rajangam, MD, PhD, President, Head of R [...]

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts

21/04/2025 - 15:15

Vancouver, Canada, April 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]

Hapbee Technologies Launching Highly Anticipated ‘Boosted Signals’ Feature with Upcoming New App Release

21/04/2025 - 15:15

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies, Inc. (TSXV: HAPB | OTCQB: HAPBF | FSE: HA1), a digital wellness technology company, today announced the upcoming rollout of a [...]

Kham's House From Grief to Grace: One Mother’s Mission to Support Young Cancer Warriors Now Celebrates Three Years of Hope

21/04/2025 - 16:00

Dallas, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Kham’s House announces its 3-year anniversary celebration, unveiling an expanded slate of services for adolescents and young adults (AYAs) facing cancer and life-altering [...]

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

21/04/2025 - 12:00

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve [...]

Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis

21/04/2025 - 12:00

Independent Cost-Effectiveness Analysis Concludes Nociscan is Effective and Less Costly Compared to Provocative Discography Conclusions Illustrate Nociscan Saves $1,712 per Patient and Improves Surgical Success by 10% [...]

Alumis and ACELYRIN Announce Amended Merger Agreement

21/04/2025 - 12:30

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company [...]